Re your figures timber, GSK quarterlies pre-July 11 show an average US quarterly Arixtra sales figure of around $65-70M.
Your calculation of $89M makes sense, but it's much higher than historical GSK data.
Based on the GSK figures, RDY is getting 30% of pre-generic sales.
open briefing, page-40
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable